Skip to content
DataLookout
Menu

ASC4YoungNCT07681258

A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region

StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved at least 2 months later across 2 updates.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 4 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Start date pushed from Oct 29, 2026 to Dec 1, 2026
    • Primary and study completion pushed from Jul 30, 2027 to Sep 1, 2027
  2. Notable Eligibility criteria expanded, about 6 words
    • Primary and study completion pushed from Jun 30, 2027 to Jul 30, 2027
    • Start date: Sep 30, 2026 to Oct 29, 2026
    • Secondary endpoints: details revised at 3 of 19 entries
  3. Notable Start date: Jun 30, 2026 to Sep 30, 2026v2
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Major Molecular Response (MMR) Rate in Young Adults
Timeframe: Approximately 12 Months

Secondary (19)

Incidence of Adverse Events (AEs)
Number of Patients by Type and Severity of AEs
Incidence of AEs Leading to Dose Modifications
Number of Treatment Interruptions Due to AEs
Duration of Treatment Interruptions Due to AEs
Show 14 moreShow less
Time to Treatment Discontinuation due to Adverse Events (TTDAE)
Proportion of Patients who Achieve an Early Molecular Response Milestone of BCR::ABL1 IS ≤ 10% After 3 Months of Treatment
Proportion of Patients who Achieve an Early Molecular Response Milestone of BCR::ABL1 IS ≤ 1% After 6 Months of Treatment
MMR in Patients Aged > 40 years
Rate of Deep Molecular Response
Number of Patients With Prior Tyrosine Kinase Inhibitor (TKI) Treatment
Duration of CML at Time of Asciminib Treatment Initiation
Asciminib Starting Dose
Number of Patients With Dose Modifications
Number of Treatment Interruptions
Duration of Treatment Interruptions
Number of Patients by Reasons for Treatment Interruptions and Subsequent Treatment Switching
Number of Patients by Reason for Treatment Switch
Number of Patients by Clinicopathological Characteristics

Arms and interventions

Young Adults Cohort

CML patients aged ≤ 40 years at the first documented asciminib administration.

Older Adults Cohort

CML patients aged \> 40 years at the first documented asciminib administration.